RESEARCH ARTICLE

CHRNA5 rs16969968 Polymorphism Association with Risk of Lung Cancer - Evidence from 17,962 Lung Cancer Cases and 77,216 Control Subjects

Zhi-Wei Xu1*, Guan-Nan Wang2*, Zhou-Zhou Dong1, Tao-Hong Li1, Chao Cao3*, Yu-Hong Jin1*

Abstract

Background: Genetic studies have shown a possible relationship between the rs16969968 polymorphism in CHRNA5 and the risk of lung cancer. However, the results have been conflicting. Thus we rigorously conducted a meta-analysis to clarify any association. Methods: A total of 10 case-control studies involving 17,962 lung cancer cases and 77,216 control subjects were analysed. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to measure the strength of the association. Results: We found the CHRNA5 rs16969968 polymorphism to be associated with the risk of lung cancer (AA vs GG: OR=1.60, 95%CI=1.51-1.71). On stratified analysis by smoking status, a statistically significant increased risk was observed in the smoking group (AA vs GG: OR=1.80, 95%CI=1.61-2.01). However, this polymorphism was not associated with lung cancer risk in Asians (AA vs GG: OR=0.95, 95%CI=0.35-2.59), whereas it was linked to increased risk of lung cancer among Caucasians (AA vs GG: OR=1.65, 95%CI=1.55-1.76). Conclusions: Our meta-analysis provided statistical evidence for a strong association between rs16969968 polymorphism and the risk of lung cancer, especially in smokers and Caucasians. Application of this relationship may contribute to identification of individuals at high risk of lung cancer and indicate a chemoprevention target.

Keywords: rs16969968 - polymorphism - lung cancer - CHRNA5 - meta-analysis

Asian Pac J Cancer Prev, 16 (15), 6685-6690

Introduction

Lung cancer is one of the leading causes of malignancy-related death and has become a major public health problem worldwide. It accounts for 17% of all new cancer cases and kills more people than any other cancer (Jemal et al., 2011). The exact underlying molecular mechanisms of lung cancer remain unknown. Although tobacco smoking and exposure to several occupational and environmental carcinogens are known risk factors for lung cancer, they are insufficient to explain the different lung cancer morbidity in the same exposure. Therefore, some host factors including genetic polymorphism have attracted significant interest in the study of pulmonary tumorigenesis (Toh et al., 2006; Ahmad et al., 2015).

The subunits CHRNA5/A3/B4 on chromosome 15q25 are considered to be correlated with smoking-related disease and nicotine addiction (Weiss et al., 2008; Saccone et al., 2009; Ware et al., 2011). These subunits are well known to encode the nicotine–acetylcholine receptors (nAChRs), which are the original physiological product in the central and peripheral nervous systems after smoking tobacco. Moreover, nicotine can induce cellular proliferation, tumour invasion, and angiogenesis, and it inhibits apoptosis mediated by nAChRs (Dasgupta et al., 2006; Dasgupta et al., 2009; Liu et al., 2010). In addition, Falvella et al. (2009) detected an obvious up-regulation of the CHRNA5 gene in lung tumour tissue. Thus, single nucleotide polymorphism (SNP) variant in CHRNA5 may influence the strength of cancer risk.

SNP at rs16969968 leads to the transposition of aspartic acid (G allele) to asparagine (A allele) at amino-acid position 398 (D398N) of the CHRNA5 protein (Weiss et al., 2008). Recently, the relationship between genetic variants of the rs16969968 in CHRNA5 and lung cancer risk has drawn tremendous attention. A study carried out on a Norwegian population implicated a more than 2-fold increased risk of lung cancer associated with the AA genotype carriers compared with the carriers of the GG genotype (Gabrielsen et al., 2013). However, in another report, the investigators demonstrated that CHRNA5 rs16969968 might have a limit effect on the susceptibility to lung cancer (Islam et al., 2013). Given these conflicting results, it is essential to perform a quantitative synthesis of...
the evidence with rigorous methods. We conducted a meta-analysis on published large-scale case-control studies to evaluate the association between the rs16969968 polymorphism and the susceptibility of lung cancer.

**Materials and Methods**

**Publication search strategy**

We searched MEDLINE, Web of Science, and EMBASE databases to identify studies published before June 2015 using combinations of the search terms: (rs16969968 OR D398N) AND (gene OR polymorphism OR genetic variant) AND (lung cancer). Trials were not excluded on the basis of language. All available studies were retrieved. The abstracts of relevant scientific meetings were also examined to ensure complete review of the available studies. If genotype frequency data were not provided in the published articles, we attempted to contact the corresponding author for additional studies and the missing data.

**Selection criteria**

The specific inclusion criteria to the meta-analysis were as follows: case-control studies, estimated correlations of the rs16969968 polymorphism and lung cancer risk, supply of the available genotype frequency both in case and control groups, and adequate published data for evaluating odds ratios (ORs) with 95% confidence intervals (CIs). Only large-scale case-control studies with a minimum of 100 subjects were included in our meta-analysis.

**Data extraction**

Two authors independently extracted data and reached a consensus on all of the available items, including the first author (ref.), published year, ethnicity (each of the ethnic groups categorized as Caucasians, Asians, etc.), definition of cases, genotype determination methods, smoking conditions, matching situations, and genotyping information. Firstly, we considered the allele comparison model (A vs. G), homozygous genotype comparison (AA vs. GG), heterozygote genotype comparison (AG vs. GG), recessive effect model comparison (AA vs. AG + GG), and dominant effect model comparison (AA + AG vs. GG). In addition, subgroup analyses were conducted according to smoking status and ethnicity (Caucasians vs. Asians).

**Statistical analysis**

This meta-analysis was used the Hardy–Weinberg equilibrium (HWE) to measure the frequencies of the genotype about each control group compared with expected genotype. OR and 95%CI of each case-control group were used to estimate the intensity of correlation of rs16969968 polymorphisms with lung cancer risk. The Q statistic test was performed to evaluate the heterogeneity between individual studies, and p<0.1 was considered significant. The I^2 test was used to measure the strength of the heterogeneity, with I^2=0 representing absolute consistency and I^2<25%, 25 - 75%, and>75% representing low, moderate, and high degrees of inconsistency, respectively (Higgins et al., 2003; Cao et al., 2012). The fixed-effect model was selected when the strength was assumed to be homogeneous; otherwise, the random-effect model was used. We also performed the Z-test to determine the significance of the combined OR; P<0.05 was regarded as significant. Egger’s test and a funnel plot were used to assess publication bias (Egger et al., 1997; Higgins and Thompson, 2002). All data were analysed with Stata (Version 12.0, Stata Corporation) and Review Manager (Version 5.0.24, the Cochrane Collaboration), and all of the P values were two-sided.

**Results**

**Characteristics of included studies**

The detailed steps for selecting studies process are shown in Figure 1. A total of 50 studies concerning the rs16969968 polymorphism in CHRNA5 with lung cancer were initially searched and screened for full text. Twenty-one studies were considered as potentiality. Of these, eleven studies were excluded due to data was
not available (Hung et al., 2008; Shiraishi et al., 2009; Carcereny et al., 2010; Hansen et al., 2010; Sasaki et al., 2010; Yang et al., 2010; Wojas-Krawczyk et al., 2012; Spitz et al., 2013; Walsh et al., 2013; He et al., 2014) and one study was duplicate publications (Timofeeva et al., 2011). Ten articles (Young et al., 2008; Falvella et al., 2009; Zienolddiny et al., 2009; Lips et al., 2010; Truong et al., 2010; Jaworowska et al., 2011; Sakoda et al., 2011; Wei et al., 2011; Gabrielsen et al., 2013; Islam et al., 2013) met the inclusion criteria. The basic characteristics and genotype prevalence of these articles are shown in Table 1. Lung cancer cases were mostly histologically or cytologically diagnosed, and controls were free of cancer.

**Quantitative synthesis**

Ten studies including 17,962 lung cancer patients and 77,216 control subjects were used to assess the association between rs16969968 polymorphism and lung cancer risk. A statistically significant association between lung cancer and rs16969968 polymorphism was found under homozygote comparison (OR=1.60, 95%CI=1.51-1.71, \( P<0.00001; \ P=0.32, \ I^2=14\%\) for heterogeneity) (Figure 2 and Table 2). Similar results were observed in the other gene models tested: allele comparison (OR=1.28, 95%CI=1.24-1.31, \( P<0.00001; \ P=0.59, \ I^2=0\%\) for heterogeneity), dominant genetic model (OR=1.33, 95%CI=1.28-1.39, \( P<0.00001; \ P=0.44, \ I^2=0\%\) for heterogeneity), recessive genetic model (OR=1.42, 95%CI=1.34-1.51, \( P<0.00001; \ P=0.65, \ I^2=0\%\) for heterogeneity), and heterozygote comparison (OR=1.27, 95%CI=1.22-1.32, \( P<0.00001; \ P=0.54, \ I^2=0\%\) for heterogeneity).

The effect of rs16969968 genotype on lung cancer risk was also evaluated in stratified analysis by smoking status. A statistically significant association between the rs16969968 genotype and lung cancer risk in the smoker group was found in all the gene models tested (homozygote comparison: OR=1.80, 95%CI=1.61-2.01, \( P<0.00001; \ P=0.62, \ I^2=0\%\) for heterogeneity). However, there was no association between rs16969968 and lung cancer risk in the non-smoker group (homozygote comparison: OR=1.06, 95%CI=0.48-2.34) (Figure 3).

In the stratification analyses for ethnicity, the effect of rs16969968 genotype on lung cancer risk increased with statistical significance in Caucasians under all genetic models (homozygote comparison: OR=1.65, 95%CI=1.55-1.76, \( P<0.00001; \ P=0.55, \ I^2=0\%\) for heterogeneity). However, this polymorphism was not associated with risk of lung cancer in Asians (homozygote comparison: OR=0.95, 95%CI=0.35-2.59) (Table 2 and Figure 4).

**Sensitivity analysis**

We performed sensitivity analysis sequentially by omission of individual studies. None of the pooled ORs were significantly influenced by any single study in the whole cohort or stratified analysis. The distribution of genotypes in the controls of Wei et al (Wei et al., 2011) was not consistent with Hardy-Weinberg equilibrium. When this study was excluded, the pooled OR was not significantly affected (homozygote comparison: OR=1.60, 95%CI=1.50-1.71, \( P<0.00001; \ P=0.24, \ I^2=23\%\) for heterogeneity).
other words, individuals that carried the AA genotype of CHRNA5 with preclinical work (Fowler et al., 2011). In was obviously increased in mice with a null mutation in the same cigarettes than non-carriers. Furthermore, Fowler showed that patients with AA genotype of rs16969968 and 77,216 control subjects. The results from our study showed that patients with AA genotype of rs16969968 have a 1.60-fold higher risk for the development of lung cancer than that of GG genotype.

The findings of this study might have some alternative explanations. The potential gene–environment interactions should be considered. In a genome-wide association study, Sacconers et al. initially demonstrated that rs16969968 in CHRNA5 is related to nicotine dependence (Saccone et al., 2007). Subsequently, those findings were supported by several studies (Bierut et al., 2008; Hung et al., 2008). It is generally accepted that tobacco smoking is a major risk factor for the development of lung cancer. Interestingly, the levels of plasma nicotine and tobacco-specific carcinogens among AA carriers are higher than those of non-carriers with the same smoking exposure (Le Marchand et al., 2008). It is possible that smokers can adjust the nicotine intake dose from a cigarette by altering their puffing time and depth. That is to say, smokers with the AA genotype inhale more toxicants by smoking the same cigarettes than non-carriers. Furthermore, Fowler et al. reported that this gene was involved in nicotine self-administration. It was reported that nicotine intake was obviously increased in mice with a null mutation in CHRNA5 with preclinical work (Fowler et al., 2011). In other words, individuals that carried the AA genotype of rs16969968 increased their lung cancer risk by altering nicotine self-administration (Macqueen et al., 2014). On the other hand, another plausible explanation is that the variant of rs16969968 alters mRNA expression of CHRNA5. Falvella et al. (Falvella et al., 2009) revealed that CHRNA5 proteins express in tumour cells but not in stromal cells through immunohistochemical analysis. The relationship between this polymorphism and lung cancer remained significant after adjustment for cigarette smoking. Moreover, the researchers observed an increased risk of lung cancer in those who never smoked (Lips et al., 2010). This evidence supports that rs16969968 directly affects lung cancer risk.

As expected, the stratification analysis by smoking showed a remarkable association between the rs16969968 genotype and lung cancer. The lung cancer risk regarding genotype was found to be increased in the smoker group (OR=1.80, 95%CI=1.61-2.01), whereas little association was observed in non-smokers (OR=1.06, 95%CI=0.48-2.34). In the stratified analysis by ethnicity, AA genotype carriers were found to have a 1.65-fold higher risk of suffering lung cancer compared with GG carriers in Caucasians (OR=1.65, 95%CI=1.55-1.76), but not for Asians (OR=0.95, 95%CI=0.35-2.59). The results may be due to the difference in ethnicity, and environmental exposures may affect allele frequency in rs16969968, which modified the risk of lung cancer. However, the findings in non-smokers and Asians should be interpreted with caution, because there were only one or two studies involving in the relevant populations. More studies based on larger populations should be conducted to further confirm these findings.

There were some limitations inherent in the study design. For instance, only a few studies were conducted to investigate the polymorphism and risk of lung cancer in non-smokers and in Asian populations. Therefore, there was insufficient power to support some conclusions in the subgroup analyses. Furthermore, our further valuation of potential gene-gene and gene-environment interactions was limited by the lack of original data.

There are several advantages in this meta-analysis. Firstly, only large-scale studies were included in our study, and some of them were genome-wide association study (GWAS) (Lips et al., 2010; Wei et al., 2011). The results of this meta-analysis were consistent with the findings of the genome-wide studies publications. Secondly, all studies were case-control research and contained the available genotype frequency. Thirdly, almost of all of these studies were histologically or cytologically diagnosed, and controls were free of cancer. Notably, the control subjects of most studies were well matched with the case patients regarding age, race, sex, and smoking status. Fourthly, there was no significant heterogeneity in all genetic contrasts.

To our best knowledge, this study is the first to synthetically analysis to investigate the association between CHRNA5 rs16969968 polymorphism and the risk of lung cancer. We demonstrated that the rs16969968 polymorphism was associated with lung cancer risk. Furthermore, similar results were observed in smokers and among Caucasians. Further large-scale research is needed to confirm these findings.
anticipated to verify our findings, and particularly, studies among different populations and non-smokers with lung cancer should be conduct in future research. Demonstrating this relationship may contribute to identifying individuals with high risk or indicate chemoprevention targets.

References

Ahmad D, Bakairy AK, Katheri AM, et al (2015). MDM2 (RS769412) G>A Polymorphism in cigarette smokers: a clue for the susceptibility to smoking and lung cancer risk. Asian Pac J Cancer Prev, 16, 4057-60.

Bierut LJ, Stitzel JA, Wang JC, et al (2008). Variants in Nicotinic Receptors and Risk for Nicotine Dependence. Am J Psychiat, 165, 1163-71.

Cao C, Sun SF, Lv D, et al (2013). Utility of VEGF and sVEGFR-1 in bronchoalveolar lavage fluid for differential diagnosis of primary lung cancer. Asian Pac J Cancer Prev, 14, 2443-6.

Cao C, Wang R, Wang J, et al (2012). Body mass index and lung cancer risk. Int J Cancer, 131, 2515-20.

Cao C, Sun SF, Lv D, et al (2013). Utility of VEGF and sVEGFR-1 in bronchoalveolar lavage fluid for differential diagnosis of primary lung cancer. Asian Pac J Cancer Prev, 14, 2443-6.

Cao C, Wang R, Wang J, et al (2012). Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One, 7, 43892.

Carcereny E, Ramirez JL, Sanchez-Ronco M, et al (2010). Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients. Lung Cancer-J Iaslc, 68, 491-7.

Chen Z, Xu Z, Sun S, et al (2014). TGF-beta1, IL-6, and TNF-alpha in bronchoalveolar lavage fluid: useful markers for lung cancer? Sci Rep, 4, 5595.

Dasgupta P, Kinkade R, Joshi B, et al (2006). Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Nail Acad Sci U S A, 103, 6332-7.

Dasgupta P, Rizwani W, Pillai S, et al (2009). Nicotine induces cell proliferation, invasion and epithelial-mesenchymal transition in a variety of human cancer cell lines. Int J Cancer, 124, 36-45.

Egger M, Davey SG, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.

Falveilla FS, Galvan A, Frullanti E, et al (2009). Transcription deregulation at the 15q25 locus in association with lung adenocarcinoma risk. Clin Cancer Res, 15, 1837-42.

Fowler CD, Lu Q, Johnson PM, et al (2011). Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature, 471, 597-601.

Gabrielsen ME, Romundstad P, Langhammer A, et al (2013). Association between a 15q25 gene variant, nicotine-related habits, lung cancer and COPD among 56,307 individuals from the HUNT study in Norway. Eur J Hum Genet, 21, 1293-9.

Hanssen HM, Xiao Y, Rice T, et al (2010). Fine mapping of chromosome 15q25-1 lung cancer susceptibility in African-Americans. Hum Mol Genet, 19, 3652-61.

He P, Yang XX, He XQ, et al (2014). CHRNA3 Polymorphism Modifies Lung Adenocarcinoma Risk in the Chinese Han Population. Int J Mol Sci, 15, 5446-57.

Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.

Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.

Hung RJ, McKay JD, Gaborieau V, et al (2008). A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature, 452, 633-7.

Islam MS, Ahmed MU, Sayeed MS, et al (2013). Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 polymorphism and lung cancer - a meta-analysis. Jpn J Clin Oncol, 43, 1167-75.

Jaworowska E, Trubicka J, Lener MR, et al (2011). Smoking related cancers and loci at chromosomes 15q25, 5p15, 6p22.1 and 6p21.33 in the Polish population. PLoS One, 6, 25057.

Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.

Le Marchand L, Derby KS, Murphy SE, et al (2008). Smokers with the CHRNA lung cancer-associated variants are exposed to higher levels of nicotine equivalents and a carcinogenic tobacco-specific nitrosamine. Cancer Res, 68, 9137-40.

Lips EH, Gaborieau V, McKay JD, et al (2010). Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17,000 individuals. Int J Epidemiol, 39, 563-577.

Liu JZ, Tozzi F, Waterworth DM, et al (2010). Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet, 42, 436-40.

Macqueen DA, Heckman BW, Blank MD, et al (2014). Variation in the alpha 5 nicotinic acetylcholine receptor subunit gene predicts cigarette smoking intensity as a function of nicotine content. Pharmacogenomics J, 14, 70-76.

Sacco NL, Sacco SF, Hinrichs AL, et al (2009). Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am J Med Genet B Neuropsychiatr Genet, 150, 453-66.

Sacco SF, Hinrichs AL, Saccoke NL, et al (2007). Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet, 16, 36-49.

Sakoda LC, Loomis MM, Doherty JA, et al (2011). Chromosome 15q24-25.1 variants, diet, and lung cancer susceptibility in cigarette smokers. Cancer Causes Control, 22, 449-61.

Sasaki H, Hikosaka Y, Okuda K, et al (2010). CHRNAs gene D398N polymorphism in Japanese lung adenocarcinoma. J Surg Res, 162, 75-78.

Shiraishi K, Kohno T, Kunitoh H, et al (2009). Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. Carcinogenesis, 30, 65-70.

Spitz MR, Amos CI, Land S, et al (2013). Role of selected genetic variants in lung cancer risk in African Americans. J Thorac Oncol, 8, 391-7.

Timofeeva MN, McKay JD, Smith GD, et al (2011). Genetic polymorphisms in 15q25 and 19q13 loci, cotinine levels, and risk of lung cancer in EPIC. Cancer Epidemiol Biomarkers Prev, 20, 2250-61.

Toh CK, Gao F, Lim WT, et al (2006). Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol, 24, 2245-51.

Truong T, Hung RJ, Amos CI, et al (2010). Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst, 102, 959-971.

Walsh KM, Gorlov IP, Hansen HM, et al (2013). Fine-mapping of the 5p15.33, 6p22.1-2p12.1, and 15q25.1 regions identifies functional and histology-specific lung cancer susceptibility loci in African-Americans. Cancer Epidemiol Biomarkers Prev, 22, 251-60.

Ware JJ, van den Bree MB, Munafò MR (2011). Association of the CHRNA5-A3-B4 gene cluster with heaviness of smoking: a meta-analysis. Nicotine Tob Res, 13, 1167-75.

Wei C, Han Y, Spitz MR, et al (2011). A case-control study of a 15q25 variant and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 20, 2603-9.
Weiss RB, Baker TB, Cannon DS, et al (2008). A candidate gene approach identifies the CHRNA5-A3-B4 region as a risk factor for age-dependent nicotine addiction. PLoS Genet, 4, 1000125.

Wojas-Krawczyk K, Krawczyk P, Biemacka B, et al (2012). The polymorphism of the CHRNA5 gene and the strength of nicotine addiction in lung cancer and COPD patients. Eur J Cancer Prev, 21, 111-7.

Yang P, Li Y, Jiang R, et al (2010). A rigorous and comprehensive validation: common genetic variations and lung cancer. Cancer Epidemiol Biomarkers Prev, 19, 240-4.

Young RP, Hopkins RJ, Hay BA, et al (2008). Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur Respir J, 32, 1158-64.

Zienolddiny S, Skaug V, Landvik NE, et al (2009). The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. Carcinogenesis, 30, 1368-71.